唑来膦酸钠对围绝经期综合征伴骨质疏松患者的临床疗效及IL-8、IL-10、骨钙素水平的影响  

Effect of zoledronate on the clinical efficacy and IL-8,IL-10 and osteocalcin levels in perimenopausal with osteoporosis

作　　者：方健[1] 蒋宋怡[2] 郑颖 FANG Jian JIANG Song-yi ZHENG Ying(Department of Pharmacy, Hangzhou Third People’s Hospital of Yuhang District,Hangzhou, 3 1 1 1 1 5 Department of Orthopedics, Sir Run Run Shaw Hospital School of Medicine of Zhejiang University, Hangzhou 310016, China Department of Chronic Diseases, Community Health Service Center of Yuhang District, Hangzhou 311121, China)

机构地区：[1]杭州市余杭区第三人民医院药剂科,浙江杭州311115 [2]浙江大学医学院附属邵逸夫医院骨科,浙江杭州310016 [3]杭州市余杭区仓前社区卫生服务中心慢病管理科,浙江杭州311121

出　　处：《中国生化药物杂志》2016年第12期87-90,共4页Chinese Journal of Biochemical Pharmaceutics

摘　　要：目的唑来膦酸钠对围绝经期综合征伴骨质疏松患者的临床疗效及白细胞介素-8（interleukin-8,IL-8）、白细胞介素-10（interleukin-10,IL-10）、骨钙素水平的影响。方法选取2014年1月~2015年3月在杭州市余杭区第三人民医院的72例围绝经期综合征伴骨质疏松患者,随机分为2组,每组36例。对照组患者予常规口服碳酸钙D3以及阿尔法D3治疗,观察组在此基础上再给予唑来膦酸钠静脉滴注,连续治疗4 w。检测治疗前及治疗后患者血清炎性因子及骨代谢指标,测定视觉模拟评分法（visual analongue scale,VAS）及骨密度,比较其临床疗效。结果与治疗前比较,2组血清碱性磷酸酶（alkaline phosphatase,ALP）、血清骨钙素（bone glaprotein,BGP）水平及VAS评分显著降低（P〈0.05）,IL-8、肿瘤坏死因子-α（tumor necrosis factor,TNF-α）水平降低（P〈0.05）,IL-10水平升高（P〈0.05）,腰椎（L1~4）、双髋以及股骨颈的骨密度（bone mineral density,BMD）均升高（P〈0.05）;与对照组比较,血清ALP、BGP水平及VAS评分较低（P〈0.05）,IL-8、TNF-α水平较低（P〈0.05）,IL-10水平较高（P〈0.05）,腰椎（L1~4）、双髋以及股骨颈的BMD较高（P〈0.05）,治疗有效率较高（P〈0.05）。结论唑来膦酸钠治疗围绝经期综合征伴骨质疏松临床疗效显著,能有效缓解机体炎性症状及骨关节疼痛,抑制骨量的减少。Objective To investigate the effect of zoledronate on the clinical efficacy and IL-8,IL-10 and osteocalcin levels in perimenopausal women with osteoporosis. Methods A total of 72 cases menopausal syndrome with osteoporosis from January 2014 to March 2015 in Hangzhou Third People＇s Hospital of Yuhang District were randomly divided into two groups with 36 cases in each group. Patients in the control group were treated with routine oral administration of calcium carbonate D3 and alpha D3,and the observation group was treated with zoledronate acid sodium on this basis for four weeks. Serum inflammatory factor and bone metabolism index were measured before and after treatment,VAS score and bone mineral density were measured,and the clinical effect was compared. Results Compared with before treatment,two groups of serum ALP,BGP levels and VAS score were significantly decreased（ P〈0. 05）,IL-8 and TNF-α levels decreased（ P〈0. 05）,IL-10 level increased（ P〈0. 05）,lumbar（ L1 ~ 4）,bilateral hip and femoral neck BMD increased（ P〈0. 05）; compared with the control group,serum ALP,BGP levels and VAS score in the observation group was lower（ P〈0. 05）,IL-8,TNF-α levels were lower（ P〈0. 05）,IL-10 level was higher（ P〈0. 05）,lumbar（ L1 ~ 4）,bilateral hip and femoral neck BMD were higher（ P〈0. 05）,the treatment effective rate was higher（ P〈0. 05）. Conclusion Zoledronate in the treatment of perimenopausal syndrome with osteoporosis is significant clinical efficacy,it can effectively relieve the inflammatory symptoms and bone and joint pain,inhibit bone reduction.

关 键 词：围绝经期综合征 骨质疏松 唑来膦酸钠 骨钙素 

分 类 号：R977.5[医药卫生—药品]